Vivo Capital Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 29
- Investments
- 276
- Portfolio
- 67
- Exits
- 174
Vivo Capital General Information
Description
Founded in 1996, Vivo Capital is a healthcare-focused venture capital firm based in Palo Alto, California. The firm seeks to invest in biopharmaceuticals, specialty pharmaceuticals, medical devices, and other subsectors of healthcare and life sciences companies.
Contact Information
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 192 Lytton Avenue
- Palo Alto, CA 94301
- United States
+1 (650) 000-0000
Vivo Capital Investments (276)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| RayzeBio | 09-Jun-2021 | Later Stage VC | 00000 | Drug Discovery | Pre-Clinical Trials | |
| 00000000 00000000 | 27-May-2021 | 00000 00000 | 0000 | Surgical Devices | Generating Revenue | 000000 0000000 |
| 0000 000000000000 | 26-May-2021 | 00000 00000 | 00000 | Biotechnology | Generating Revenue | 0000 00 |
| 0000000 0000000000 | 25-May-2021 | 0000 | 0000 | Biotechnology | Generating Revenue | |
| 0000 0000000000 | 17-May-2021 | 0000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 00000000 0000 00.0 |
| 0000 00000000000 | 10-May-2021 | 00000 00000 | 00000 | Diagnostic Equipment | Generating Revenue/Not Profitable | 000000 0000000 |
| 0000000000 | 06-May-2021 | 00 000000000 | 0000 | Other Devices and Supplies | Generating Revenue | 000000 0000000 |
| 000000 00000000 | 23-Apr-2021 | 00000 00000 | Machinery (B2B) | Generating Revenue | ||
| Satsuma Pharmaceuticals | 31-Mar-2021 | PIPE | 0000 | Pharmaceuticals | Generating Revenue/Not Profitable | |
| Immune-Onc Therapeutics | 30-Mar-2021 | Later Stage VC | 000.00 | Drug Discovery | Clinical Trials - General |
Vivo Capital Exits (174)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Impel NeuroPharma | 22-Apr-2021 | IPO | 0000 |
| 000000 00000000000 | 26-Mar-2021 | 000 | 00000 |
| 0000000000 0000000 | 01-Mar-2021 | 000000000000000000 | 00000 |
| 0000000 | 24-Feb-2021 | 000000000000000000 | |
| 0000 0000000000000 | 05-Feb-2021 | 000 | 00000 |
| 00000 000000000000 | 05-Feb-2021 | 000 | 00000 |
| 00000000 000000000 | 29-Jan-2021 | 0000000000 | |
| 0000000 000 | 22-Jan-2021 | 000000 0000000000 | 00000 |
| Gracell | 08-Jan-2021 | IPO | 00000 |
| ALX Oncology | 10-Dec-2020 | Public Investment 2nd Offering | 00000 |
Vivo Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is available in the PitchBook Platform. To explore Vivo Capital‘s full profile, request access.
Request a free trialVivo Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialVivo Capital Team (52)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Daisy Xu | Managing Director | Palo Alto, CA | |||
| DanDan Dong Ph.D | Managing Director | 0 | 0 | 0 | Palo Alto, CA |
| David Liu Ph.D | Managing Director | Palo Alto, CA | |||
| Gaurav Aggarwal MD | Managing Director | 0 | 0 | 0 | Palo Alto, CA |
| Joseph Siletto | Managing Director | 0 | 0 | 0 | Palo Alto, CA |
Vivo Capital Co-Investors (260)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 13 | 0 |
|
|
|
| venBio | 00 | 0 | 0 |
|
|
| Cormorant Asset Management | 00 | 0 | 0 |
|
|
| RA Capital Management | 00 | 0 | 0 |
|
|
| Lilly Asia Ventures | 00 | 0 |
|
|